Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia

Udo Kontny, Thomas J. Walsh, Jochen Rossler, Markus Uhl, Charlotte M. Niemeyer

Research output: Contribution to journalArticlepeer-review

Abstract

This report documents the clinical activity of caspofungin in a 13-year-old girl with acute myeloid leukemia (AML) and chronic disseminated candidiasis (CDC), refractory to amphotericin B and fluconazole. Caspofungin was started at 50 mg/d resulting in a temporary response. With no further clinical improvement and radiological progress after 2 months of therapy, the dose of caspofungin was increased to 100 mg/d, leading to a sustained clinical response. Therapy was given for a total of 12 months and had no attributable adverse effects. This approach resulted in successful treatment of refractory CDC with caspofungin.

Original languageEnglish (US)
Pages (from-to)360-362
Number of pages3
JournalPediatric Blood and Cancer
Volume49
Issue number3
DOIs
StatePublished - Sep 2007

Keywords

  • AML
  • Infections in immunocompromised hosts
  • New agents
  • Pediatric oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this